Atlas Trials

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Clinical trial NCT03238196 · COMPLETED

Trial details

NCT number
NCT03238196
Sponsor
Vanderbilt-Ingram Cancer Center
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2017-08-18
Primary completion
2021-04-30
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.